Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AMLSAN DIEGO and ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Leukapheresis Market Driven by Rising Blood-Related Disorders, Advanced Technologies, and Growing Demand for Personalized Medicine, the ...

Texas Tech Physicians nurse practitioner Sara Tello recommended a comprehensive and compassionate approach for people trying to quit smoking, v ...

Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a fixed dose subcutaneously (SC) via an on-body delivery system (OBDS) in ...

Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.